Marcelo Iastrebner1, Joaquín Castro2, Edgardo García Espina3, Carolina Lettieri4, Silvio Payaslian5, María Celia Cuesta6, Pablo Gutiérrez Fernández7, Araceli Mandrile8, Angela Paola Contreras9, Sebastián Gervasoni10, Gabriel Verde11, Cayetano Galetti12, Estefanía Minoldo13, Vanesa Caruso14. 1. Clínica Zabala. ruxopublication@protonmail.com. 2. Clínica Zabala, Swiss Medical Group, Buenos Aires. drjoaquincastro@gmail.com. 3. Clínica Zabala, Swiss Medical Group, Buenos Aires. edgardoge@gmail.com. 4. Clínica Zabala, Swiss Medical Group, Buenos Aires. caroletti23@gmail.com. 5. Clínica Zabala, Swiss Medical Group, Buenos Aires. SilvioP@swissmedical.com.ar. 6. Clínica Zabala, Swiss Medical Group, Buenos Aires. mcuesta@intramed.net. 7. Clínica Zabala, Swiss Medical Group, Buenos Aires. Pablo.Gutierrezfernandez@swissmedical.com.ar. 8. Hospital General de Agudos "Parmenio Piñero", Buenos Aires. araceli_mandrile@hotmail.com. 9. Hospital General de Agudos "Parmenio Piñero", Buenos Aires. Dra.apcontreras2326@yahoo.com. 10. Hospital General de Agudos "Parmenio Piñero", Buenos Aires. sebagerva@gmail.com. 11. . gverde@hotmail.com. 12. Sanatorio Allende, Córdoba. cgalletti21@gmail.com. 13. Sanatorio Allende, Córdoba. estefaniaminoldo@hotmail.com. 14. Hospital General de Agudos "Parmenio Piñero", Buenos Aires. vanesacaruso060974@gmail.com.
Abstract
Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this prospective, multicenter, single arm (compared with a historical control), add-on, experimental phase 2 study, ruxolitinib 5 mg BID was added to standard of care in COVID-19 patients. Main objective was to determine efficacy and safety of ruxolitinib in patients with COVID-19-related SARS. Results: Even though we could not show a significant reduction of COVID-19 pneumonia patients requiring intensive care unit admission and mechanical ventilation (primary endpoint), a trend to a lower mortality rate in critical ill patients receiving ruxolitinib was reported. Administered ruxolitinib dose had to be increased according to protocol in 32% of patients, without additional toxicity. Conclusion: Side effects profile was manageable, and no direct organ injury was caused by the study drug. Ruxolitinib had a fast anti-inflammatory effect, and one-third of patients felt well immediately after starting treatment. Universidad Nacional de Córdoba
Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this prospective, multicenter, single arm (compared with a historical control), add-on, experimental phase 2 study, ruxolitinib 5 mg BID was added to standard of care in COVID-19 patients. Main objective was to determine efficacy and safety of ruxolitinib in patients with COVID-19-related SARS. Results: Even though we could not show a significant reduction of COVID-19 pneumonia patients requiring intensive care unit admission and mechanical ventilation (primary endpoint), a trend to a lower mortality rate in critical ill patients receiving ruxolitinib was reported. Administered ruxolitinib dose had to be increased according to protocol in 32% of patients, without additional toxicity. Conclusion: Side effects profile was manageable, and no direct organ injury was caused by the study drug. Ruxolitinib had a fast anti-inflammatory effect, and one-third of patients felt well immediately after starting treatment. Universidad Nacional de Córdoba
Authors: Hannah M Komar; Gregory Serpa; Claire Kerscher; Erin Schwoegl; Thomas A Mace; Ming Jin; Ming-Chen Yang; Ching-Shih Chen; Mark Bloomston; Michael C Ostrowski; Phil A Hart; Darwin L Conwell; Gregory B Lesinski Journal: Sci Rep Date: 2017-05-11 Impact factor: 4.379
Authors: José Luis Merino; Marcel Martínez-Cossiani; Angel Iniesta; Carlos Escobar; Juan R Rey; Sergio Castrejón-Castrejón Journal: Europace Date: 2020-10-01 Impact factor: 5.214
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Mustafa Buyukozkan; Sergio Alvarez-Mulett; Alexandra C Racanelli; Frank Schmidt; Richa Batra; Katherine L Hoffman; Hina Sarwath; Rudolf Engelke; Luis Gomez-Escobar; Will Simmons; Elisa Benedetti; Kelsey Chetnik; Guoan Zhang; Edward Schenck; Karsten Suhre; Justin J Choi; Zhen Zhao; Sabrina Racine-Brzostek; He S Yang; Mary E Choi; Augustine M K Choi; Soo Jung Cho; Jan Krumsiek Journal: iScience Date: 2022-06-17